Orchestra BioMed
OBIO
48 hedge funds and large institutions have $97.8M invested in Orchestra BioMed in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 5 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
10.57% more ownership
Funds ownership: 39.72% → 50.29% (+11%)
2% more funds holding
Funds holding: 47 → 48 (+1)
16% less capital invested
Capital invested by funds: $116M → $97.8M (-$18.1M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$16.9M |
| 2 |
PA
Perceptive Advisors
New York
|
+$13.4M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$573K |
| 4 |
BlackRock
New York
|
+$506K |
| 5 |
State Street
Boston,
Massachusetts
|
+$309K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFG
SVB Financial Group
Dallas,
Texas
|
-$1.04M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$262K |
| 3 |
MHS
M Holdings Securities
Portland,
Oregon
|
-$162K |
| 4 |
Bank of New York Mellon
New York
|
-$119K |
| 5 |
IIA
IPG Investment Advisors
San Diego,
California
|
-$108K |
OBIO Hedge Fund Activity: Q3 2024 in Review
48 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q3 2024, worth a combined $97.8M — down 16% from $116M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new OBIO positions and 5 closed out — a net gain of 1 holder — while 21 added to existing stakes and 10 trimmed.
The largest buyer was RTW Investments, adding an estimated $16.9M. The largest seller was SVB Financial Group, exiting entirely with an estimated $1.04M sold.
- 48 institutional investors held Orchestra BioMed (OBIO) as of Q3 2024, up from 47 in Q2 2024.
- Funds reported $97.8M of Orchestra BioMed stock for Q3 2024, down 16% quarter-over-quarter.
- 6 funds opened new Orchestra BioMed positions in Q3 2024 and 5 closed out, a net change of +1 holder.
- The largest Orchestra BioMed buyer in Q3 2024 was RTW Investments, an estimated $16.9M added.
- The largest Orchestra BioMed seller in Q3 2024 was SVB Financial Group, an estimated $1.04M sold.
Based on aggregated 13F filings for Q3 2024.